Drug application
LIBERVANT (DIAZEPAM)
Drugs@FDA NDA 212641 · AQUESTIVE
Key facts
| Drug name | LIBERVANT |
|---|---|
| Active ingredients | DIAZEPAM |
| Application type | NDA |
| Application number | 212641 |
| Company | AQUESTIVE |
| Dosage forms | FILM, BUCCAL |
| Strength | 5MG |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission class | Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval |
| Latest submission status date | Aug 30, 2022 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: